(2E)-3-[[4-叔丁基苯基]磺酰基]-2-丙烯腈 | 196309-76-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (2E)-3-[[4-叔丁基苯基]磺酰基]-2-丙烯腈
• 英文名称: (2E)-3-[(4-tert-butylphenyl)sulfonyl]acrylonitrile
• 英文别名: Bay 11-7082；Bay 11-7085；(2E)-3-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-2-propenenitrile；(E)-3-(4-t-butylphenylsulfonyl)-2-propenenitrile；(E)-3-(4-tert-butylphenylsulfonyl)acrylonitrile；(E)-3-(4-tert-butylphenyl)sulfonylprop-2-enenitrile
• CAS: 196309-76-9
• 化学式: C₁₃H₁₅NO₂S
• 分子量: 249.334
• InChiKey: VHKZGNPOHPFPER-ONNFQVAWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  66.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2E)-3-[[4-叔丁基苯基]磺酰基]-2-丙烯腈 在 三乙胺 、 4-叔丁基苯硫酚 作用下， 以 氯仿 为溶剂， 反应 3.0h， 以97%的产率得到(E)-3-(4-tert-butyl-phenylsulfanyl)acrylonitrile
  参考文献：
  名称：

  Synthesis and biological evaluation of sulfonyl acrylonitriles as novel inhibitors to peritoneal carcinomatosis

  摘要：

  The vast majority of cancer patients die from metastasis, the process by which cancer cells spread to secondary tissues through body fluids. Peritoneal carcinomatosis is a type of metastasis in which cancer cells gain access to the intra-abdominal cavity and then implant in the peritoneum, the thin tissue that lines the abdominal wall and internal organs. Unfortunately, peritoneal carcinomatosis can occur following surgical resection of intra-abdominal malignancies. We previously reported proapoptotic activity of (2E)-3-[[4-(1,1-dimethylethyl) phenyl] sulfonyl]-2-propenenitrile (BAY 11-7085, 1) on colon and pancreatic cancer cells during adhesion and demonstrated that this compound could significantly inhibit peritoneal carcinomatosis in mice.(1,2) In order to determine the chemical basis of the anti-metastatic properties of BAY 11-7085, a series of analogs were synthesized and evaluated for their ability to induce apoptosis in pancreatic and ovarian cancer cells during adhesion to mesothelial cells, which line the surface of the peritoneum. The co-culture assay results were validated using a murine peritoneal carcinomatosis model. These analogs may greatly benefit patients undergoing surgical resections of colorectal, pancreatic, and ovarian cancers depending on their tolerability. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.085

文献信息

• Substituted Aromatic Sulfur Compounds and Methods of Their Use
  申请人：Cephalon, Inc.

  公开号：US20140005175A1

  公开（公告）日：2014-01-02

  Compounds of formula II are described: wherein D, n, R a , R b , and R c are as herein defined, along with pharmaceutical compositions and methods of using compounds of formula II for treating or reducing the risk of peritoneal carcinomatosis in a patient.

  描述了化学式II的化合物：其中D、n、Ra、Rb和Rc的定义如本文所述，以及使用化学式II的化合物治疗或减少患者腹膜癌转移风险的药物组合物和方法。
• Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug
  申请人：The Regents of the University of California

  公开号：US10029017B2

  公开（公告）日：2018-07-24

  Disclosed herein, the invention pertains to methods and compositions that find use in treatment, diagnosis, prognosis and characterization of disease and disease samples based on the ability of a disease sample to cleave a MTS molecule of the present invention. The MTS molecules of the present invention have a formula as disclosed herein and wherein A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X and Y are linkers; P is a pre-targeting moiety; M is a macromolecular carrier, C is a detectable moiety; and T is a compound for delivery to a target, including for example a therapeutic compound.

  在此公开的本发明涉及根据疾病样本裂解本发明的 MTS 分子的能力用于疾病和疾病样本的治疗、诊断、预后和表征的方法和组合物。本发明的 MTS 分子具有如本文所公开的式，其中 A 是多肽，其序列包括 5 至 9 个连续的酸性氨基酸，其中氨基酸选自天冬氨酸和谷氨酸；B 是多肽，其序列包括 5 至 20 个连续的碱性氨基酸；X 和 Y 是连接体；P 是预靶向分子；M 是大分子载体；C 是可检测分子；T 是用于递送至靶点的化合物，例如包括治疗化合物。
• Personalized protease assay to measure protease activity in neoplasms
  申请人：The Regents of the University of California

  公开号：US10385380B2

  公开（公告）日：2019-08-20

  Disclosed herein, the invention pertains to methods and compositions that find use in diagnostic, prognostic and characterization of neoplasia samples based on the ability of a neoplasia sample to cleave a MTS molecule of the present invention. In some embodiments, a MTS molecule disclosed herein has the formula (A-X-B-C), wherein A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X is a linker; and C is a detectable moiety.

  本发明涉及根据肿瘤样本裂解本发明 MTS 分子的能力，用于诊断、预后和表征肿瘤样本的方法和组合物。在一些实施方案中，本发明公开的 MTS 分子具有式（A-X-B-C），其中 A 是多肽，其序列包括 5 至 9 个连续的酸性氨基酸，其中氨基酸选自天冬氨酸和谷氨酸；B 是多肽，其序列包括 5 至 20 个连续的碱性氨基酸；X 是连接体；C 是可检测分子。
• Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof
  申请人：The Regents of the University of California

  公开号：US10596259B2

  公开（公告）日：2020-03-24

  Disclosed herein, the invention pertains to methods and compositions that find use in radiosensitization of tumors and tumor samples based on the ability of a tumor sample to cleave a MTS molecule of the present invention. The MTS molecules of the present invention have a formula as disclosed herein and wherein A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X and Y are linkers; P is an optional pre-targeting moiety; M is an optional macromolecular carrier; and T is a radiosensitization agent for delivery to a target, including for example a therapeutic compound.

  本发明涉及根据肿瘤样品裂解本发明MTS分子的能力对肿瘤和肿瘤样品进行放射增敏的方法和组合物。本发明的MTS分子具有如本文所公开的式，其中A是具有包含5至9个连续酸性氨基酸序列的多肽，其中氨基酸选自天冬氨酸和谷氨酸；B是具有包含5至20个连续碱性氨基酸序列的多肽；X和Y是连接体；P是任选的前靶向分子；M是任选的大分子载体；T是用于递送至靶点（例如包括治疗化合物）的放射增敏剂。
• Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostics and therapeutic delivery
  申请人：The Regents of the University of California

  公开号：US11021517B2

  公开（公告）日：2021-06-01

  The present invention provides methods for guiding preservation of human neurons or human nerves during surgery by administering a fluorescently-labeled peptide that specifically binds to the human neurons or human nerves. The invention further provides human neuron or nerve targeting molecules comprising fluorescently-labeled peptides that specifically bind to human neurons or human nerves and compositions thereof.

  本发明提供了在手术过程中通过施用能与人神经元或人神经特异性结合的荧光标记肽来指导保存人神经元或人神经的方法。本发明进一步提供了人类神经元或神经靶向分子，包括特异性结合人类神经元或人类神经的荧光标记肽及其组合物。